This outcome was supported by Augusto et al. 2022, which revealed increased SOD levels and resolution of NAFLD‐related lesions with simultaneous metformin and atorvastatin use. This evidence concerns the gene SOD1 and metabolic dysfunction-associated steatotic liver disease.